I-FDA ivuma i-Keytruda pembrolizumab njenge-lineotherapy yokuqala yomdlavuza womdlavuza osezingeni eliphezulu

Izindlela zokwelapha ze-Rna Bases

Lokhu ukugunyazwa kwezidakamizwa kwe-9th FDA okusekelwa ucwaningo lwe-Stand Up To Cancer.

I-FDA muva nje igunyaze i-immunotherapy pembrolizumab njengokwelashwa komugqa wokuqala kweziguli ezinezinhlobo ezithile ze umdlavuza we-colorectal othuthukile. Lokhu ukuvunywa kwe-9th FDA okusekelwa ucwaningo lwe-Stand Up To Cancer® (SU2C).

Iziguli ezisanda kutholakala zine- ukungazinzi okuphezulu noma kwe-metastatic microsatellite (MSI-H) or ukungalungi kokungasebenzi kahle (dMMR) umdlavuza obomvu phambilini bekuzobekwa i-pembrolizumab kuphela ngemuva kokuqeda amandla ukwelashwa okujwayelekile kwamakhemikhali.

I-pembrolizumab evunyiwe yi-FDA, eyaziwa nangaphansi kwegama lomkhiqizo Keytruda, njengokwelashwa komugqa wokuqala i-metastatic MSI-H — i-dMMR umdlavuza obomvu ngokuya ngemiphumela yokuqala evela esivivinyweni somtholampilo sesigaba III, esasikhokhelwe ingxenye yesibonelelo sikaSU2C.

"Uma kuqhathaniswa nokwelashwa kwendabuko, i-pembrolizumab yayiphezulu nemiphumela emibi embalwa ye-MSI-H-dMMR colorectal iziguli," kusho uLuis A. Diaz, MD, oyiNhloko yeDivision of Solid Tumor Oncology e-Memorial Sloan Kettering Cancer Center kanye nomholi we Iqembu le-SU2C Colorectal Cancer Dream, okwenze ucwaningo. "Kuneminye umdlavuza wesimila esiqinile kubantu abadala nasezinganeni ezinala maphutha afanayo e-MSI-H — dMMR, ngakho-ke ucwaningo lwethu lungahle lube nezinye izinhlobo zomdlavuza."

Cishe i-4-5% yamathumba omdlavuza we-metastatic ane-MSI-H — dMMR biomarkers, okubangelwa ukwehluleka kwamaseli ukulungisa amaphutha enziwe ngesikhathi senqubo yokuhlukaniswa kwamangqamuzana futhi kungaholela ekukhuleni okwengeziwe kwesimila.

Lolu cwaningo lubandakanye iziguli ezingama-307 ze-MSI-H — dMMR ezinomdlavuza ongalawuleki emazweni angama-23 abelashwa nge-pembrolizumab noma ngamakhemikhali ajwayelekile. I-Pembrolizumab ihlose futhi ivimbe iprotheni ebizwa nge-PD-1 engavimbela amaseli omzimba abizwa ngama-T cell ekuqedeni amaseli omdlavuza ngempumelelo.

UDkt.Diaz nethimba lakhe bathole ukuthi iziguli ezinomdlavuza we-MSI-H — dMMR eziphathwe nge-pembrolizumab azibonanga umdlavuza wazo usakazeka izinyanga eziyi-16.5 eziphakathi, uma kuqhathaniswa neziguli eziphathwe ngamakhemikhali ajwayelekile abone ukuthi izicubu zawo zikhula ngemuva kwezinyanga eziyi-8.2 eziphakathi. Iziguli ezithola i-chemotherapy ejwayelekile nazo zibe nemiphumela emibi kakhulu kuneziguli ezithola i-pembrolizumab. Imiphumela ephelele yokufunda zanyatheliswa kwiNew England Journal of Medicine ngoDisemba 2, 2020.

"Ithimba le-Stand Up To Cancer Colorectal Cancer Dream libe negalelo elibonakalayo ekwelashweni okungcono kwezindlela ze-MSI-H - dMMR colorectal iziguli," kusho owazuza umklomelo kaNobel uPhillip A. Sharp, PhD, usihlalo weStand Up To Cancer Advisory Committee kanye uprofesa weSikhungo eDavid H. Koch Institute for Integrative Cancer Research eMassachusetts Institute of Technology. "Lesi yisibonelo esihle sendlela yokubambisana yocwaningo lwe-Stand Up To Cancer ethinta ngqo izimpilo zeziguli ezinomdlavuza."

Umdlavuza omnyama yi imbangela yesibili ejwayelekile yokufa komdlavuza phakathi kwamadoda nabesifazane baseMelika bahlanganisiwe futhi bacishe Ama-148,000 aseMelika bazothola ukuxilongwa okusha komdlavuza we-colon noma we-rectal ngo-2020. Ngenkathi amazinga okufa komdlavuza obomvu ehle kakhulu ngenxa yokwanda kokuhlolwa nokuthuthukiswa kwezokwelapha, mayelana Umuntu omdala oyedwa kwabathathu uneminyaka engama-1 noma ngaphezulu ungakutholi ukuhlolwa okunconyiwe. Amacala amasha omdlavuza obala ngokwezibalo okwenzeka ngezinga elikhulayo phakathi kwabantu abadala abancane nabaseminyakeni ephakathi nendawo e-US, ngenani lamacala omdlavuza wobala kubantu abangaphansi kweminyaka engama-50 okulindeleke ukuthi bacishe baphindwe kabili by 2030.

Njengoba umdlavuza onamabala uqhubeka nokuba nomthelela ongahlukanisi kubantu bombala
(Abantu abamnyama banamanani aphezulu kakhulu yomdlavuza omnyama wanoma yiluphi uhlanga noma uhlanga e-US), ukuthuthuka kokuhlolwa kanye nokunemba okusha kanye nokwelashwa okuhlosiwe kufanele kufinyelele kuzo zonke iziguli. AbakwaSU2C bamemezele i-Health Equity Initiative ngoJanuwari 2020. Lolu hlelo ludinga wonke amaqembu asesikhathini esizayo afuna izimali zeStand Up To Cancer ukubhekana nokuqashwa nokugcinwa kweziguli ezivela emaqenjini ehlukene ezinhlanga nezinhlanga kanye nemiphakathi enganakiwe ukuze kuthuthukiswe ukubamba iqhaza okuhlukahlukene ezivivinyweni zomtholampilo zomdlavuza. Lolu hlelo lubandakanya ukusebenzisana namaqembu abameli kanye nabasekeli bezimboni nabezinkampani ukuhambisa phambili imizamo yocwaningo kanye nokuqwashisa umphakathi.

Ithimba le-SU2C Colorectal Cancer Dream Team liphethwe ngumlingani wesayensi we-Stand Up To Cancer, i Association American for Cancer Research.

Source:

Sukuma Umele Umdlavuza

UMirabai Vogt-James
310-739-5576

I-Journal reference:

U-André, T., et al. (2020) Pembrolizumab in Microsatellite-Instability – High Advanced Colorectal Cancer. I-New England Journal of Medicinedoi.org/10.1056/NEJMoa2017699.

IMozocare iyinkundla yokufinyelela kwezokwelapha ezibhedlela nasemitholampilo ukusiza iziguli zithole ukunakekelwa okungcono kwezempilo ngamanani aphansi.

Ngemininingwane engaphezulu ungaxhumana nathi kwa-mozo@mozocare.com noma ushayele + 91-8826883200